{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T09:06:55Z","timestamp":1793869615537,"version":"4.6.1"},"reference-count":20,"publisher":"Tech Science Press","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["oncol res"],"published-print":{"date-parts":[[2019,5,7]]},"abstract":"<jats:p>Regorafenib is a multikinase inhibitor for the treatment of metastatic colorectal cancer. Regorafenib-induced hand\u2010foot skin reaction (HFSR) is a common side effect during treatment. The reported frequency of HFSR was 80% (grade 3: 28%) in the Japanese subpopulation in the CORRECT\n trial; however, more detailed data regarding HFSR in terms of onset and sites of susceptibility are unclear. Additionally, the risk factors for regorafenib-induced severe HFSR are unknown. The aim of this study was to compare HFSR between the hands and feet and identify preexisting risk factors\n for severe HFSR in Japanese patients receiving regorafenib. We retrospectively examined the onset and severity of HFSR on the hands and feet of patients with metastatic colorectal cancer treated with regorafenib from May 2013 to October 2015 in the Cancer Institute Hospital of the Japanese\n Foundation for Cancer Research. In addition, we examined the possible association between preexisting clinical factors and severe HFSR. Our results showed that no significant difference in the incidence of HFSR of any grade was observed between the hands (71%) and feet (74%) (<jats:italic>p<\/jats:italic>\u2009=\u20090.63).\n The incidence of grade 3 HFSR was more frequent on the feet (33%) than on the hands (8%) (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.01). The onset of grade 3 HFSR was earlier on the feet than on the hands (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). No preexisting risk factor was identified. Our findings indicate\n that severe HFSR was more prevalent on the feet than on the hands, suggesting the need for appropriate screening for early detection and treatment of regorafenib-induced HSFR.<\/jats:p>","DOI":"10.3727\/096504018x15291727589740","type":"journal-article","created":{"date-parts":[[2018,6,19]],"date-time":"2018-06-19T01:06:40Z","timestamp":1529370400000},"page":"551-556","source":"Crossref","is-referenced-by-count":9,"title":["Regorafenib-Induced Hand\u2010Foot Skin Reaction Is More Severe on the Feet Than on the Hands"],"prefix":"10.32604","volume":"27","author":[{"given":"Yuma","family":"Nonomiya","sequence":"first","affiliation":[{"name":"Division of Chemotherapy, Faculty of Pharmacy, Keio University, Minato-ku, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Yokokawa","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Koto-ku, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuyoshi","family":"Kawakami","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Koto-ku, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuo","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Koto-ku, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Aoyama","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Koto-ku, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomomi","family":"Takiguchi","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Koto-ku, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahito","family":"Sugisaki","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Koto-ku, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Koto-ku, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsukuni","family":"Suenaga","sequence":"additional","affiliation":[{"name":"Department of Gastroenterological Chemotherapy, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Koto-ku, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeru","family":"Wakatsuki","sequence":"additional","affiliation":[{"name":"Department of Gastroenterological Chemotherapy, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Koto-ku, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kensei","family":"Yamaguchi","sequence":"additional","affiliation":[{"name":"Department of Gastroenterological Chemotherapy, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Koto-ku, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshikazu","family":"Sugimoto","sequence":"additional","affiliation":[{"name":"Division of Chemotherapy, Faculty of Pharmacy, Keio University, Minato-ku, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiro","family":"Hama","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Koto-ku, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"17807","reference":[{"key":"b1","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/ijc.25864","article-title":"Regorafenib (BAY 73-4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity","volume":"129","year":"2011","journal-title":"Int J Cancer"},{"key":"b2","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0140-6736(12)61900-X","article-title":"Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): An international, multicentre, randomised, placebo-controlled, phase 3 trial","volume":"381","year":"2013","journal-title":"Lancet"},{"key":"b3","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1007\/s10637-014-0154-x","article-title":"Randomized phase III trial of regorafenib in metastatic colorectal cancer: Analysis of the CORRECT Japanese and non-Japanese subpopulations","volume":"33","year":"2015","journal-title":"Invest New Drugs"},{"key":"b4","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1093\/annonc\/mdg500","article-title":"Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: Safety results of a randomized, phase III trial","volume":"14","year":"2003","journal-title":"Ann Oncol."},{"key":"b5","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1177\/1060028015594451","article-title":"Risk factors exacerbating hand-foot skin reaction induced by capecitabine plus oxaliplatin with or without bevacizumab therapy","volume":"49","year":"2015","journal-title":"Ann Pharmacother."},{"key":"b6","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1158\/1078-0432.CCR-08-1141","article-title":"Hand-foot skin reaction increases with cumulative sorafenib dose and with combination anti-vascular endothelial growth factor therapy","volume":"15","year":"2009","journal-title":"Clin Cancer Res."},{"key":"b7","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1093\/annonc\/mdr580","article-title":"Development and validation of a prediction index for hand-foot skin reaction in cancer patients receiving sorafenib","volume":"23","year":"2012","journal-title":"Ann Oncol."},{"key":"b8","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1159\/000448717","article-title":"Self-reported adherence to trifluridine and tipiracil hydrochloride for metastatic colorectal cancer; a retrospective cohort study","volume":"91","year":"2016","journal-title":"Oncology"},{"key":"b9","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S1470-2045(15)70156-7","article-title":"Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"16","year":"2015","journal-title":"Lancet Oncol."},{"key":"b10","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1016\/j.ejca.2011.05.007","article-title":"Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma","volume":"47","year":"2011","journal-title":"Eur J Cancer"},{"key":"b11","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/ajco.12163","article-title":"Sunitinib in metastatic renal cell carcinoma: An ethnic Asian subpopulation analysis for safety and efficacy","volume":"10","year":"2014","journal-title":"Asia Pac J Clin Oncol."},{"key":"b12","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1186\/s12885-016-2440-9","article-title":"Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: Results from a multicenter study (REBACCA) nested within a compassionate use program","volume":"16","year":"2016","journal-title":"BMC Cancer"},{"key":"b13","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/nrc1970","article-title":"Mechanisms of cutaneous toxicities to EGFR inhibitors","volume":"6","year":"2006","journal-title":"Nat Rev Cancer"},{"key":"b14","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3816\/CGC.2009.n.002","article-title":"Risk of hand-foot skin reaction with the multitargeted kinase inhibitor sunitinib in patients with renal cell and non-renal cell carcinoma: A meta-analysis","volume":"7","year":"2009","journal-title":"Clin Genitourin Cancer"},{"key":"b15","first-page":"338","article-title":"Combined inhibition of VEGF- and PDGF-signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms","volume":"18","year":"2004","journal-title":"FASEB J."},{"key":"b16","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1093\/annonc\/mdn389","article-title":"Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib","volume":"19","year":"2008","journal-title":"Ann Oncol."},{"key":"b17","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1007\/s10637-013-9977-0","article-title":"Risk of hand-foot skin reaction with the novel multikinase inhibitor regorafenib: A meta-analysis","volume":"31","year":"2013","journal-title":"Invest New Drugs"},{"key":"b18","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s10637-008-9196-2","article-title":"Blackberry-induced hand-foot skin reaction to sunitinib","volume":"27","year":"2009","journal-title":"Invest New Drugs"},{"key":"b19","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s11523-009-0127-8","article-title":"Sorafenib-induced hand-foot skin reaction: A Koebner phenomenon?","volume":"4","year":"2009","journal-title":"Target Oncol."},{"key":"b20","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/S0895-4356(96)00236-3","article-title":"A simulation study of the number of events per variable in logistic regression analysis","volume":"49","year":"1996","journal-title":"J Clin Epidemiol."}],"container-title":["Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.techscience.com\/uploads\/attached\/file\/20220623\/20220623104238_27674.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,6]],"date-time":"2024-12-06T21:37:48Z","timestamp":1733521068000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.techscience.com\/or\/v27n5\/48570"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,7]]},"references-count":20,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,5,7]]}},"alternative-id":["0965-0407(20190507)27:5L.551;1-"],"URL":"https:\/\/doi.org\/10.3727\/096504018x15291727589740","relation":{},"ISSN":["0965-0407"],"issn-type":[{"value":"0965-0407","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5,7]]}}}